

Remarks

Applicant submits herewith Hickman *et al.*, *Journal of Immunology*, 171: 22-26 (2003) (Exhibit A) and Herberts *et al.*, *Human Immunology*, 64:44-55 (2003) (Exhibit B). These references are submitted to supplement the Reply filed on October 15, 2003.

Applicant respectfully requests that the Examiner consider the references in conjunction with the October 15, 2003 Reply. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Consideration of this Supplemental Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

 *Rg # 36,688*
Andrea Jo Kamage
Agent for Applicant
Registration No. 43,703


Date: 10/21/03
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

www.jimmunol.org

Volume 171 / No. 1 / July 1, 2003

IMMUNOLOGY

OF THE JOURNAL



HEALTH SCIENCES LIBRAR.
UNIVERSITY OF WISCONSIN

JUN 30 2003

1305 Linden Drive
Madison, WI 53706

IMMUNOLOGY



TABLE OF CONTENTS

THE JOURNAL OF

1 IN THIS ISSUE

3 LETTERS TO THE EDITOR

BRIEF REVIEWS

- 5 Leukotrienes, Sphingolipids, and Leukocyte Trafficking
Adam C. Yopp, Gwendolyn J. Randolph, and Jonathan S. Bromberg

- 11 Chemokine Receptors in Asthma: Searching for the Correct Immune Targets
Nicholas W. Lukacs, Allison L. Miller, and Cory M. Hogaboam

CUTTING EDGE

- 17 Cutting Edge: Rapid In Vivo CTL Activity by Polyoma Virus-Specific Effector and Memory CD8⁺ T Cells
Anthony M. Byers, Christopher C. Kemball, Janice M. Moser, and Aron E. Lukacher

- 22 Cutting Edge: Class I Presentation of Host Peptides Following HIV Infection
Heather D. Hickman, Angela D. Luis, Wilfried Bardet, Rico Buchli, Casey L. Battson, Michael H. Shearer, Kenneth W. Jackson, Ronald C. Kennedy, and William H. Hildebrand

- 27 Cutting Edge: Rapid In Vivo Killing by Memory CD8 T Cells
Daniel L. Barber, E. John Wherry, and Rafi Ahmed

- 32 Cutting Edge: Link Between Innate and Adaptive Immunity: Toll-Like Receptor 2 Internalizes Antigen for Presentation to CD4⁺ T Cells and Could Be an Efficient Vaccine Target
Karoline W. Schjetne, Keith M. Thompson, Nadra Nilsen, Trude H. Flo, Burkhard Fleckenstein, Jens-Gustav Iversen, Terje Espevik, and Bjørn Bogen

CELLULAR IMMUNOLOGY AND IMMUNE REGULATION

- 37 The Uterine NK Cell Population Requires IL-15 but These Cells Are Not Required for Pregnancy nor the Resolution of a *Listeria monocytogenes* Infection
Ellen M. Barber and Jeffrey W. Pollard

On the cover: Human astrocytes assume a more activated morphology following coculture with activated T cells. Giuliani et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. *J. Immunol.* 171:368.

The Journal of Immunology (ISSN 0022-1767) is published twice each month by The American Association of Immunologists, 9650 Rockville Pike, Bethesda, MD 20814-3998. Subscription rates: U.S.A. AND POSSESSIONS: personal, \$330; institutional, \$640-\$900 (depending on number of faculty and students); single copy, \$37.00. FOREIGN (incl. Canada): personal, \$490; institutional, \$800-\$1,060 (depending on number of faculty and students); single copy, \$44.00. See www.jimmunol.org for current rate information. Air Printed Matter rates are available on request from Customer Service, *The Journal of Immunology*, Room L-2310, 9650 Rockville Pike, Bethesda, MD 20814-3998. Indexed by *Current Contents* and *Index Medicus*. Periodicals postage paid at Bethesda, MD 20814-3998 and at additional mailing offices. Country of origin U.S.A. Printed on acid-free recyclable paper. Postmaster: Send address changes to *The Journal of Immunology*, Room L-2310, 9650 Rockville Pike, Bethesda, MD 20814-3998. Copyright © 2003 by The American Association of Immunologists, Inc.

Cutting Edge: Class I Presentation of Host Peptides Following HIV Infection¹

Heather D. Hickman,* Angela D. Luis,* Wilfried Bardet,* Rico Buchli,* Casey L. Battson,[†] Michael H. Shearer,^{2*} Kenneth W. Jackson,[†] Ronald C. Kennedy,^{2*} and William H. Hildebrand^{13*}

*Class I MHC molecules bind intracellular peptides for presentation to cytotoxic T lymphocytes. Identification of peptides presented by class I molecules during infection is therefore a priority for detecting and targeting intracellular pathogens. To understand which host-encoded peptides distinguish HIV-infected cells, we have developed a mass spectrometric approach to characterize HLA-B*0702 peptides unique to or up-regulated on infected T cells. In this study, we identify 15 host proteins that are differentially presented on infected human T cells. Peptides with increased expression on HIV-infected cells were derived from multiple categories of cellular proteins including RNA binding proteins and cell cycle regulatory proteins. Therefore, comprehensive analysis of the B*0702 peptide repertoire demonstrates that marked differences in host protein presentation occur after HIV infection. The Journal of Immunology, 2003, 171: 22–26.*

Major histocompatibility complex class I molecules exist as heterotrimers composed of a H chain, L chain, and peptide ligand (1). Class I molecules sample peptides from the proteome of the cell, transport the peptides to the surface, and interface with immune effectors where they communicate cellular fitness (2). This ability to sample and report on vast numbers of intracellular proteins has earned class I molecules the nickname “nature’s gene chips” (3).

Although it has been demonstrated that MHC molecules sample a vast array of endogenous proteins during the normal cellular lifecycle, characterization of host-protein-derived peptides after HIV infection has not been performed. Therefore, a fundamental question arises: what host-encoded peptides are uniquely presented on the surface of infected cells? Based upon the observation that HIV produces and interacts with multiple host-encoded proteins inside the cell (including Tsg101 (4) and

RNA polymerase II (5)), we hypothesized that host-protein-derived peptides are uniquely presented during infection.

We previously described a bioreactor-HLA-protein production method and a mass-spectrometric-ion-mapping system for comparatively screening class I-eluted peptide ligands (6, 7). In this study, we extend this approach to test the hypothesis that HIV infection alters the presentation of host-encoded peptides. Peptides eluted from HLA-B*0702 molecules produced in HIV-infected or uninfected cells were directly compared using mass spectrometry. Comparative mapping of HIV-infected and uninfected peptides results in the identification of 15 host-derived peptides uniquely presented on HIV-infected cells.

Materials and Methods

Soluble HLA production

Soluble HLA-B*0702 transfectants were produced as described (6) using Sup-T1 cells (7). Transfectants were cultured in a Unisyn CP2500 bioreactor unit (Biovest International, Minneapolis, MN) for 2 mo with continuous peptide collection. Approximately 30 mg of soluble HLA (sHLA)⁴ were collected from either uninfected or infected cells, supplemented with 1% Triton X-100, and stored at 4°C.

HIV infection

HIV-1 strain MN was propagated in Sup-T1 transfectants and monitored by p24 ELISA (Zeptomatrix, Buffalo, NY). For cell pharma infection, 3×10^9 cells were infected at a multiplicity of infection (MOI) of 0.5. For time course protein analysis, 1×10^9 cells were infected at an MOI of 4.5 for 2 h, washed once, and replaced in RPMI 1640 + 20% FBS.

Peptide purification

B*0702 molecules were affinity purified over a W6/32 affinity column. Peptides were eluted with 0.2 N acetic acid, brought to 10% acetic acid concentration, and heated to 78°C for 10 min. Fractions were purified in a stirred cell with a 3-kDa molecular mass cutoff cellulose membrane (Millipore, Bedford, MA). Peptides were reversed-phase-HPLC fractionated using a standard gradient of acetonitrile. Separate but identical peptide purifications were done from uninfected and infected cells.

*Department of Microbiology and Immunology and [†]William K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104

Received for publication March 28, 2003. Accepted for publication May 1, 2003.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Contract NO1-AI-95360 (to W.H.H.). H.D.H. was supported by National Institutes of Health Training Grant T32AI07633.

² Current address: Department of Microbiology and Immunology, Texas Tech University, Lubbock, TX 79430.

³ Address correspondence and reprint requests to Dr. William H. Hildebrand, Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, 975 NE 10th Street, Oklahoma City, OK 73104. E-mail address: william-hildebrand@ouhsc.edu

⁴ Abbreviations used in this paper: sHLA, soluble HLA; MOI, multiplicity of infection; PARP, poly(ADP-ribose) polymerase; MS, mass spectrometry; HMG, high-mobility group protein; eIF, eukaryotic translation initiation factor; USP3, ubiquitin-specific protease 3; E6BP, E6-binding protein; HSP27, heat shock protein 27; TCP, tailless-complex protein; PTB, polypyrimidine tract-binding protein; Hu R, Hu Ag R.

NOTICE: This material may be protected by copyright law (Title 17 U.S. Code)




FIGURE 1. Mass spectrometric analysis of HLA-B*0702-bound peptides in HIV-infected cells. Peptides eluted from affinity purified sHLA were mapped on an ESI-QTOF mass spectrometer. Spectra were scanned for ion differences unique to infected cells. *A*, Initial scans were performed with windows of 200 atomic mass units and (*B*) subsequently zoomed to identify ion differences. *C*, Identified differences were subjected to MS/MS. *Top panel*, Peptide from uninfected cells; *bottom panel*, fragmentation of identical ion with identical atomic mass units in the uninfected fraction. Different fragmentation patterns indicated the absence of the peptide in the uninfected fraction. *D*, MS/MS sequence assignment from differentially expressed peptide. *E*, Synthetic peptides corresponding to putative sequence were subjected to MS/MS to verify sequence integrity.

Mass spectrometric analysis

Fractionated peptides were mapped by mass spectrometry as described (7). Peptides were nano-electrosprayed (Protana, Odense, Denmark) into a Q-Star QTOF mass spectrometer (PerSeptive Sciex, Foster City, CA). Spectra from the same fraction in uninfected/infected cells were aligned to the same mass range and visually assessed for the presence of differences that were selected for manual and automated sequence assignment using the programs BioMultiview (PerSeptive Sciex) and MASCOT (Matrix Science, London, U.K.) (8). Synthetic peptides corresponding to each putative sequence were produced and subjected to mass spectrometry MS/MS under identical collision conditions as the naturally occurring peptide and overlaid to confirm sequence identity.

Peptide binding assay

IC₅₀ values were determined using the HLA-B*0702 PolyScreen kit (Pure Protein, Oklahoma City, OK) according to the manufacturer's instructions. Fluorescently labeled control peptide and sHLA were incubated with each test peptide until equilibration of peptide replacement was reached as read on an Analyst AD plate reader (Molecular Devices, Sunnyvale, CA). IC₅₀ values were calculated using a dose-response curve.

Real-time PCR and Western blots

For Western blots, cells were lysed in electrophoresis buffer and total protein was quantified using the BCA Protein Analysis kit (Pierce, Rockford, IL). Proteins were transferred onto nitrocellulose membranes (Osmonics, Westborough, MA) before probing and detecting with commercially available Abs. For real-time PCR, total RNA was isolated using the Total RNA Isolation kit (Ambion, Austin, TX) and cDNA synthesized using the Retroscript kit. PCR was performed on a PE-7700 Light Cycler (Applied Biosystems, Foster City, CA) using primer pairs designed using Primer Express software. β -Actin was used as an internal standard. Relative transcript levels were calculated using the δ - δ cycle threshold method and normalized to zero in the uninfected cells.

Apoptosis analysis

Infected cells were treated with the Apo-Direct kit (BD Biosciences, Mountain View, CA) according to manufacturer's instructions and followed by analysis on a FACSCalibur. Poly(ADP-ribose) polymerase (PARP) cleavage was detected from the same Western blot lysates as above with an anti-PARP Ab (BD Biosciences).

Results and Discussion

Mass spectrometric mapping of peptides from infected and uninfected cells identifies 15 unique host-derived peptides

Following the harvest of B*0702/peptide complexes from both infected and uninfected cells, peptide ligands were eluted, fractionated, and each fraction was comparatively mapped using MS. Multiple peptides unique to HIV-infected cells were identified in these MS spectra (Fig. 1*A*). For example, comparison of spectra produced with peptides eluted from infected and uninfected cells identified a peak unique to the infected cells at 484.7 atomic mass units of fraction 16 (Fig. 1*B*). Peptide peaks unique to or up-regulated on HIV-infected cells were analyzed

Table I. IC₅₀ values for peptide binding to sHLA-B*0702

Peptide Sequence	IC ₅₀ (nM)
TPQDLNITML ^a	3047
SPRTLNAWV ^a	254.8
AASKERSGVSL ^b	317.3
AARPATSTL	209.8
APAYSRL	214.7
APKRPPSAF	176.1
GPRTAALGLL	257.9
IATVDSYVI	218,900
IPCLLISFL	5,980
LPQANRDTL	598.7
LPTSHPKIV	3,563
NPNQNKIVAL	1,581
QPRYPVNSV	945.5
RPYSNVSNL	227.5
SPNQARAQAAL	926.3
STTAICATGL	248,100
TPQSNRPVM	466

^a Control peptide, HIV-derived.

^b Control peptide, self-derived.

Table II. HLA-B*0702 peptides differentially presented on infected cells

Peptide Sequence	Source Protein	Abbreviation	Main Cellular Function
APKRPPSAF	High mobility group protein 1/2	HMG 1/2	DNA binding
TPQSNRPV ^m	RNA polymerase II, polypeptide A	RNA pol	Transcription
SPNQARAQAAL	Polypyrimidine tract-binding protein	PTB	mRNA processing and stability
NPNQKNVAL	Hu Ag R (ELAV-like 1) ^b	Hu R	mRNA processing and stability
AARPATSTL	Eukaryotic translation initiation factor 4GI	eIF4G	Translation
QPRYPVNSV	Tailless complex protein 1, α polypeptide	TCP-1	Cytoplasmic protein chaperone
APAYSRAL	Heat shock protein 27	HSP27	Cytoplasmic protein chaperone
STTAICATGL	Ubiquitin-specific protease 3	USP3	Ubiquitin pathway
GPRTAALGLL	E6 binding protein (reticulocalbin 2) ^b	E6BP	Unknown; ubiquitin pathway?
IPCLLISFL	Cholinergic receptor, α 3 polypeptide	CholR	Signal transduction
RPYSVNSL	Set-binding factor 1	SBF-1	Cell growth and differentiation
LPQANRDTL	MgcRacGap	MRG	Cell growth and differentiation
LPTSHPKIV	Suppressin	Sup	Cell cycle regulator
MAMMAALMA	Spark-like protein 1 (hevin) ^b	Spark-like	Antiadhesive extracellular matrix protein
IATVDSYVI	Tenascin C (hexabrachion) ^b	TenC	Similar to antiadhesive extracellular matrix protein

^a Oxidized methionine.^b Protein possessing more than one common name.

with tandem MS (Fig. 1, C and E). De novo sequence identification from MS/MS fragmentation patterns was performed on each peak unique to or up-regulated on infected cells (Fig. 1, D and E). Putatively identified ligands were analyzed for their predicted tandem MS fragmentation pattern (Fig. 1D) and compared with the spectra produced from uninfected cells (Fig. 1C). As a final confirmation of sequence integrity, peptides corresponding to the putative ligand sequences were synthesized and fragmented (Fig. 1E). Only peptides with identical experimental and control MS/MS fragmentation patterns were selected for further analyses.

As an independent verification of correct sequence assignment, we performed peptide-binding assays on each of the peptides identified through mass spectrometry. Synthetic peptides representing the peptide sequence were used in competition against a fluorescently labeled control peptide for binding to sHLA B*0702 molecules; IC₅₀ values were established for each peptide (Table I). All synthetic peptides bound to HLA-B*0702, most as strongly as the B*0702 control peptides. These data, combined with MS/MS fragmentation pattern analysis, confirmed that MS sequence analysis had yielded the correct ligand sequences.

Peptides presented at altered levels during HIV infection were derived from host proteins involved in multiple cellular pathways

Comparison of mass spectra from peptides eluted from infected and uninfected cells yielded 15 self protein-derived peptides showing altered expression on HIV-infected cells. These host-encoded peptides could be categorized by primary cellular function (Table II). Several of the peptides derived from proteins involved in RNA transcription or translation; peptides NPNQKNVAL and SPNQARAQAAL are both fragments of mRNA binding proteins, while the source protein for APKRPPSAF, high-mobility group protein (HMG) 1, facilitates the binding of transcription factors to DNA sequences (9). Another ligand in this category (AARPATSTL) derived from eukaryotic translation initiation factor (eIF) 4GI, a protein that plays a key role in cap-dependent mRNA translation initiation (10).

A second category of peptides unique to HIV-infected cells derived from cellular proteins involved in protein regulation. Peptides STTAICATGL and GPRTAALGLL derived from

ubiquitin-specific protease 3 (USP3) and E6-binding protein (E6BP), respectively. Protein USP3 hydrolyzes ubiquitin-protein bonds while E6BP can bind and alter the activity of a known ubiquitin ligase (11). Peptides APAYSRAL and QPRYPVNSV derived from source proteins heat shock protein 27 (HSP27) and tailless-complex protein (TCP)-1 (Table II) and participate in protein folding as cytoplasmic chaperones (12, 13).




FIGURE 2. Transcriptional and protein levels of peptide-source proteins during a mixed-HIV infection of sHLA-B*0702 transfectants. *A*, Relative transcript levels of peptide source proteins as determined by real-time PCR. *B*, Western blot analysis of peptide-source proteins before (–HIV) and after (+HIV) infection.




FIGURE 3. Kinetics of protein alterations during HIV infection of sHLA-B*0702 transfectants. Transfectants were infected with HIV MN and analyzed at 24-h intervals postinfection. *A*, Percentage of cells undergoing apoptosis and CD4 down-regulation during infection as determined by flow cytometry. Percent viability was determined by forward and side scatter. *B*, sHLA secretion and p24 secretion as measured by ELISA. *C*, Apoptosis analysis by Western blotting for PARP cleavage. *D*, Western blots of proteins representing unique peptides. *E*, Kinetics of protein changes during infection.

Unique peptides were derived from host proteins with altered protein levels during infection

Unique presentation of peptides during infection could be the result of multiple alterations inside the infected cell. Because HIV has been shown to transcriptionally up-regulate cellular genes (14) and gene overexpression can result in presentation by class I molecules (15), transcriptional up-regulation of genes representing unique peptides could be occurring before peptide presentation. To test this interpretation, real-time PCR was performed on mRNA transcripts from infected cells (Fig. 2*A*). Because the bioreactor system used for the harvest of sHLA proteins from infected cells represented a mixture of cells at different points in infection, T cells were infected with HIV and fed bi-weekly with uninfected cells. Once syncytia were evident visually, cells were pelleted, lysed, and real-time PCR was performed on ex-

tracted mRNA. Little change in the transcriptional level of the proteins examined was found. Thus, there was no pattern of transcriptional activation that would account for an overabundance of particular MHC-bound peptides on the infected cells.

A second possible mechanism for the presentation of unique peptides during infection was fluctuation in the levels of cellular proteins from which the peptides were derived. To examine this possibility, we performed Western blotting on total protein lysates from the same infected cells examined by real-time PCR. All of the proteins examined—eIF4G1, polypyrimidine tract-binding protein (PTB), Hu Ag R (Hu R), TCP-1, and HSP27—decreased in protein level in infected cells, indicating that degradation or turnover of the proteins was occurring (Fig. 2*B*). Thus, protein degradation during infection was the general mechanism for unique peptide presentation during infection.

Peptide changes occur early in infection

To determine the timing of protein changes, we performed a time course infection with HIV. Sup-T1 T cells were infected with HIV-1 MN at an MOI of 4.5 and cells and supernatants were sampled at 24-h intervals postinfection. Primary indicators of HIV infection were apparent early in the time course; almost 100% of cells exhibited down-regulation of CD4 by day 2 (Fig. 3A), while p24 release from infected cells began on day 4 (Fig. 3B). Flow cytometric measurement of cell viability and apoptosis (Fig. 3A) showed that a majority of the cells remained viable throughout the infection while TUNEL staining indicated that only one-fourth of the cells were undergoing apoptosis by day 8. As a secondary measurement of apoptosis, PARP cleavage was detected on day 7 (Fig. 3C). Interestingly, secretion of class I from infected cells precipitously dropped at day 5 (Fig. 3B), before the onset of apoptosis. These data indicate that cell death and apoptosis occur at late time points during infection of Sup-T1 T cells with HIV strain MN and that class I secretion predominates at early time points.

After establishing the kinetics of infection, Western blots were performed on the host proteins represented by overabundant peptides (Fig. 3D). Three of the proteins exhibited degradation by day 3 postinfection, including eIF4G, TCP-1 α , and PTB. Western blots further showed that HSP27, Hu R, and HMG 1/2 were up-regulated 1–2 days postinfection before dropping to lower levels later in the infection. The viral proteins envelope (gp120) and p24 (by ELISA) became apparent at day 4 of infection. As demonstrated in the mixed bioreactor infection, decreased levels of source proteins eIF4G, TCP-1 α , and PTB during HIV infection were not a result of decreased mRNA production (measured by real-time PCR at days 1–4, data not shown). Taken together, these data indicate that HLA-B*0702 presentation of unique peptides occurs as a result of protein changes occurring early in HIV infection (Fig. 3E).

In summary, the analysis of the HLA-B*0702 repertoire after HIV infection reveals a series of host-protein-derived peptides presented uniquely by infected cells. The host peptides most likely are presented as the result of protein level fluctuations that occur early during HIV infection. The consequence of these overabundant self peptides during infection is currently unknown but fits well into the paradigm of autoimmunity; autoimmune reactions are often present in individuals suffering from AIDS (16). Immune recognition of virus-induced host epitopes such as those reported in this study could function in the induction of autoimmune responses directly through increasing the concentration of self peptides on the cell surface.

Indeed, this mechanism is supported by a recent study demonstrating autoreactivity following measles virus-induced up-regulation of self peptides (17). Irrespective of possible function, these host-derived peptide ligands provide an expanded view of peptide presentation to the immune system following viral infection.

Acknowledgments

We thank P. Parham for helpful comments on the manuscript.

References

1. Bjorkman, P. J., M. A. Saper, B. Samraoui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. *Nature* 329:506.
2. Zinkernagel, R. M., and P. C. Doherty. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 248:701.
3. Shastri, N., S. Schwab, and T. Serward. 2002. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. *Annu. Rev. Immunol.* 20:463.
4. Garrus, J. E., U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Core, R. L. Rich, et al. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. *Cell* 107:55.
5. Herrmann, C. H., and A. P. Rice. 1995. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. *J. Virol.* 69:1612.
6. Prilliman, K. R., K. W. Jackson, M. Lindsey, J. Wang, D. Crawford, and W. H. Hildebrand. 1999. HLA-B15 peptide ligands are preferentially anchored at their C termini. *J. Immunol.* 162:7277.
7. Hickman, H. D., C. L. Batson, K. R. Prilliman, D. L. Crawford, K. L. Jackson, and W. H. Hildebrand. 2000. C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. *Hum. Immunol.* 61:1339.
8. Perkins, D. L., M. Z. Lai, J. A. Smith, and M. A. Geffer. 1989. Identical peptides recognized by MHC class I and II-restricted T cells. *J. Exp. Med.* 170:279.
9. Das, D., and W. M. Scofield. 2001. The binding interaction of HMG-1 with the TATA-binding protein/TATA complex. *J. Biol. Chem.* 276:32597.
10. Ohlmann, T., M. Rau, V. M. Pain, and S. J. Morley. 1996. The C-terminal domain of eukaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E. *EMBO J.* 15:1371.
11. Sloper-Mould, K. E., H. J. Eyre, X. W. Wang, G. R. Sutherland, and R. T. Baker. 1999. Characterization and chromosomal localization of USP3, a novel human ubiquitin-specific protease. *J. Biol. Chem.* 274:26878.
12. Rogalla, T., M. Ehtsperger, X. Preville, A. Kotlyarov, G. Lutsch, C. Ducas, C. Paul, M. Wieske, A. P. Arrigo, J. Buchner, and M. Gaestel. 1999. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. *J. Biol. Chem.* 274:18947.
13. Rommelaere, H., M. Van Troys, Y. Gao, R. Melki, N. J. Cowan, J. Vandekerckhove, and C. Ampe. 1993. Eukaryotic cytosolic chaperonin contains a complex polypeptide 1 and seven related subunits. *Proc. Natl. Acad. Sci. USA* 90:11975.
14. Simmons, A., V. Aluvihare, and A. McMichael. 2001. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. *Immunity* 14:763.
15. Castelli, C., L. Rivoltini, G. Andreola, M. Carrabba, N. Renkvist, and G. Parmiani. 2000. T-cell recognition of melanoma-associated antigens. *J. Cell. Physiol.* 182:323.
16. Ahsan, N., and E. Langhoff. 1998. Immunopathogenesis of human immunodeficiency virus. *Semin. Nephrol.* 18:422.
17. Herberts, C. A., J. van Gaans-van den Brink, E. van der Heeft, M. van Wijk, J. Hoekman, A. Jaye, M. C. Poelen, C. J. Boog, P. J. Roholl, H. Whittle, et al. 2003. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. *Hum. Immunol.* 64:44.

Human Immunology

Official Journal of the American Society
for Histocompatibility and Immunogenetics

Volume 64, Number 1, 2003

Elsevier

HEALTH SCIENCES LIBRARY
UNIVERSITY OF WISCONSIN

JAN 24 2003

1305 Linden Drive
Madison, WI 53706

Selected Papers to Appear in Forthcoming Issues

SREENARASIMHAIAH, JARAMILLO, CRIPPIN, LISKER-MELMAN, CHAPMAN, and MOHANAKUMAR
Lack of Optimal T Cell Reactivity Against the Hepatitis C Virus is Associated With the Development of
Fibrosis/Cirrhosis During Chronic Hepatitis

ALEXANDER, OSEROFF, SIDNEY, and SETTE
Derivation of HLA-B*0702 Transgenic Mice: Functional CTL Repertoire and Recognition of Human B*0702-Restricted
CTL Epitopes

STUCK, PANI, BESROUR, SEGNI, KRAUSE, USADEL, and BADENHOOP
Fas Ligand Gene Polymorphisms Are Not Associated With Hashimoto's Thyroiditis and Graves' Disease

Human Immunology is cited in *Biological Abstracts*, *Chemical Abstracts*, *Current Contents (Life Sciences)*, *MEDLINE*, *EMBASE/Excerpta Medica*, *Index Medicus*, and *Elsevier BIOBASE/Current Awareness in Biological Sciences*.

Human Immunology is published monthly by Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010. Associated personal price: EUR 194 for European countries; USD 217 for all countries except Europe and Japan; JPY 25,800 for Japan. Institutional price: EUR 1,225 for European countries; USD 1,369 for all countries except Europe and Japan; JPY 162,600 for Japan. Prices include postage and are subject to change without notice.

Regional Sales Offices: For orders, claims, product inquiries (no manuscript inquiries), please contact the Customer Support Department at the Regional Sales Office nearest to you.

New York: Elsevier Science, P.O. Box 945, New York, NY 10159-0945, USA; Tel: (+1) 212-633-3730, [Toll Free number for North American customers: 1-888-4ES-INFO (437-4636)]; Fax: (+1) 212-633-3680; E-Mail: usinfo-f@elsevier.com

Amsterdam: Elsevier Science, P.O. Box 211, 1000 AE Amsterdam, The Netherlands; Tel: (+31) 20-485-3757; Fax: (+31) 20-485-3432; E-Mail: nlinfo-f@elsevier.nl

Tokyo: Elsevier Science K.K., 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan; Tel: (+81) 3-5561-5033; Fax: (+81) 3-5561-5047; E-Mail: kyf04035@niftyserve.or.jp

Singapore: Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192; Tel: (+65) 434-3727; Fax: (+65) 337-2230; E-Mail: asiainfo@elsevier.com.sg

Single-copy and back-volume information available upon request. Claims for missing issues will be honored only up to three months for domestic addresses and six months for foreign addresses. Duplicate copies will not be sent through failure to notify Elsevier of change of address.

POSTMASTER: Send address changes to *Human Immunology*, Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010.

FOR ADVERTISING ORDERS & INQUIRIES:

North & South America: Tino DeCarlo, Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010; Tel: 212-633-3815; Fax: 212-633-3820; E-Mail: t.decarlo@elsevier.com

International: Advertising Department, Elsevier Science, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; Tel: (+44) 1865 843565; Fax: (+44) 1865 843976; E-Mail: media@elsevier.co.uk
Japan: Advertising Department, Elsevier Science K.K.; Tel: (+81) (3) 5561 5033; Fax: (+81) (3) 5561 5047

This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by the US Copyright Law. If no code appears on an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

All inquiries regarding copyrighted material from this publication, other than reproduction through the Copyright Clearance Center, should be directed to: Elsevier Science Ltd., P.O. Box 800, Oxford OX5 1DX, UK; Tel: (+44) 1865 843830; Fax: (+44) 1865 853333; E-Mail: permissions@elsevier.co.uk

© American Society for Histocompatibility and Immunogenetics, 2003. All rights reserved. Manufactured in the United States. Periodicals Postage Rate paid at New York, NY and at additional mailing offices.

∞ This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

Autoreactivity Against Induced or Upregulated Abundant Self-Peptides in HLA-A*0201 Following Measles Virus Infection

NOTICE: This material may be protected by copyright law (Title 17 U.S. Code)

Carla A. Herberts,
Jacqueline van Gaans-van den Brink,
Ed van der Heeft, Margot van Wijk, Jan Hoekman,
Assan Jaye, Martien C. M. Poelen, Claire J. P. Boog,
Paul J. M. Roholl, Hilton Whittle, Ad P. J. M. de Jong,
and Cécile A. C. M. van Els

ABSTRACT: Infectious agents have been implied as causative environmental factors in the development of autoimmunity. However, the exact nature of their involvement remains unknown. We describe a possible mechanism for the activation of autoreactive T cells induced by measles virus (MV) infection. The display of HLA-A*0201 associated peptides obtained from MV infected cells was compared with that from uninfected cells by mass spectrometry. We identified two abundant self peptides, IFI-6-16₇₄₋₈₂ and Hsp90β₅₇₀₋₅₇₈, that were induced or upregulated, respectively, following infection. Their parental proteins, the type I interferon inducible protein IFI-6-16, and the β chain of heat shock protein 90, have not been involved in MV pathogenesis. MV infection caused minor and major changes in the intracellular expression patterns of these proteins, possibly

leading to altered peptide processing. CD8⁺ T cells capable of recognizing the self-peptides in the context of HLA-A*0201 were detectable at low basal levels in the neonatal and adult human T cell repertoire, but were functionally silent. In contrast, peptide-specific producing IFN-γ producing effector cells were present in MV patients during acute infection. Thus, MV infection induces an enhanced display of self-peptides in MHC class I, which may lead to the temporary activation of autoreactive T cells. *Human Immunology* 64, 44–55 (2003). © American Society for Histocompatibility and Immunogenetics, 2003. Published by Elsevier Science Inc.

KEYWORDS: measles virus; autoimmunity; MHC class I epitopes

ABBREVIATIONS

B-LCL	B-lymphoblastoid cell line
CAD	collision activated dissociation
CBMC	cord blood mononuclear cells
ELISPOT	enzyme-linked immunospot assay
HIV-1	human immunodeficiency virus-1
HPLC	high performance liquid chromatography
Hsp90β	heat shock protein 90 β chain
IFI-6-16	type I interferon inducible protein
IFNγ	interferon γ
μLC-ESI-MS	microcapillary rpHPLC electrospray ionisation mass spectrometry

MS	mass spectrometry
MV	measles virus
MV-H	measles virus hemagglutinin
m/z	mass to charge ratio
PBMC	peripheral blood mononuclear cells
rpHPLC	reversed phase high performance liquid chromatography
SFC	spot forming cell
SPA	N-hydroxysuccinimidyl-3-pyridylacetate

From the Laboratories of Vaccine Research (C.A.H., J.v.G.v.B., M.C.M.P., C.J.P.B., C.A.C.M.v.E.), Organic Analytical Chemistry (E.v.d.H., A.P.J.M.d.J.), and Pathology and Immunobiology (M.v.W., J.H., P.J.M.R.), National Institute of Public Health and the Environment, Bilthoven, The Netherlands; and the Medical Research Council Laboratories (A.J., H.W.), Fajara, Gambia.

Address reprint requests to: Dr. Cécile van Els, Laboratory of Vaccine Research, National Institute of Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands; Tel: +31 (30) 274-3835/2219; Fax: +31 (30) 274-4429; E-mail: cecile.van.els@rivm.nl.

Received May 1, 2002; accepted July 18, 2002.

INTRODUCTION

Potentially autoreactive T cells that have escaped negative selection in the thymus are present in the periphery, but they are harmless provided they are not activated and their specific self antigen remains unexpressed on professional antigen-presenting cells (APC) in lymphoid organs [1, 2]. Despite the various mechanisms that operate to ensure peripheral tolerance [3], autoreactive T cells can be activated *in vivo* by viral or bacterial infections [4, 5], which may lead to the induction of autoimmune diseases. Many clinical findings have correlated autoimmune conditions with a particular infectious agent [6]. Measles virus (MV) infection has been associated with several autoimmune diseases [7], in particular multiple sclerosis [8, 9] and acute measles encephalomyelitis [10, 11]. How viral infections can break tolerance and thereby lead to autoimmune conditions remains largely unknown. Possible mechanisms underlying a virus-induced autoreactive T-cell response include the presentation of crossreactive antigens (molecular mimicry) [12–14], the release of otherwise sequestered antigens from immunologically privileged sites [15, 16], the modification of the antigenicity of self antigens [17], and disruption of the regulation by suppressor T cells [18]. Furthermore, an infection can specifically activate self-reactive T cells by providing appropriate costimulation [19], e.g., through the upregulation of costimulatory molecules on APC, or specifically by the release of cytokines or other molecular danger signals (bystander activation) [6, 20]. In addition, a viral infection may lead to the expression of nonphysiologic levels of self-peptides presented by major histocompatibility complex (MHC) molecules, either due to alterations in MHC class I or II expression [21, 22] as a result of the inflammatory response, or by modulating the peptide repertoire bound by MHC molecules [5, 23, 24].

To explore whether the latter mechanism may also play a role in the induction of MV associated autoimmune diseases we studied the possible shift in the MHC class I peptide display as a result of MV infection. For this, we performed a subtractive analysis of HLA-A*0201-associated peptides isolated from a human B-lymphoblastoid cell line (B-LCL) prior to and after MV infection, using sensitive mass spectrometric techniques. In addition to virus-derived peptides [25], we identified a non-viral peptide that was specifically induced by MV infection. This peptide was derived from a type I interferon inducible protein (IFI-6-16) of unknown function. Furthermore, we detected a virus-induced shift in the abundance of numerous self-peptides. From these, one abundant peptide, the expression of which was further upregulated following MV infection, was derived from

the β chain of a heat shock protein, Hsp90 β . As a member of the Hsp90 family of well-conserved, cytosolic chaperone proteins, Hsp90 is one of the most abundant heat shock proteins in eukaryotic cells, even in the absence of stress stimuli [26]. We found that T cells capable of recognizing both self-peptides in the context of HLA-A*0201 are present in the human T-cell repertoire at birth, and autoreactivity against these peptides can be detected following MV infection.

MATERIAL AND METHODS

Virus, Cell Lines, and Infection

Plaque-purified MV (Edmonston B strain), grown in Vero cells, which were cultured in DMEM supplemented with antibiotics and 10% FCS, containing 10^7 tissue culture infectious doses₅₀/ml, was used to infect the HLA-A*0201 homozygous Epstein-Barr virus (EBV) transformed B-LCL BSM, or the melanoma cell line MelJuSo at a multiplicity of infection of 1 in RPMI 1640 medium supplemented with antibiotics and 2% FCS. BSM and MelJuSo cells were cultured in RPMI 1640 medium supplemented with antibiotics and 10% FCS. The TAP deficient T2 cell line was adapted to grow in protein free hybridoma medium (PFHM) supplemented with antibiotics and 1% FCS.

Patients Studied

Cord blood, obtained from normal deliveries of newborns of 37 weeks or more of gestation, and blood samples of healthy donors were collected in The Netherlands. Blood samples from patients with measles were collected in the Gambia. All samples were collected according to the informed consent guidelines of the medical ethic committees from local hospitals. Cord blood mononuclear cells (CBMC) and peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on ficoll-hypaque (Pharmacia Biotech, Uppsala, Sweden) and cryopreserved until used in experiments. Small aliquots of cells were used for DNA preparation and molecular HLA-typing.

Peptide Synthesis

The synthetic peptides SLMSWSAIL (IFI-6-16₇₄₋₈₂) and ILDKKVEKV (Hsp90 β ₅₇₀₋₅₇₈) were prepared by standard solid phase Fmoc chemistry using an ABIMED AMS 422 simultaneous multiple peptide synthesizer (ABIMED Analysen-Technik GmbH, Langenfeld, Germany).

Isolation and HPLC Fractionation and Mass Spectrometry

HLA-A*0201 molecules were immunoprecipitated from MV-infected and uninfected BSM cells as described previously [25] using the HLA-A*0201 specific monoclonal antibody BB7.2. Peptides were eluted and fractionated in four large fractions on a 2.1 mm × 10 cm reversed-phase high performance liquid chromatography (rpHPLC) C2/C18 column (Pharmacia, SMART system) using an acetonitrile gradient (0%–60%) and 0.1% trifluoroacetic acid (TFA) in water (flow 100 µl/min).

Peptide fractions were analyzed using microcapillary rpHPLC electrospray ionisation mass spectrometry (µLC-ESI-MS) [27]. Briefly, ion traces in corresponding rpHPLC fractions of infected and uninfected cells were compared, mass by mass (abundant peptides present in both ion traces were used to assess small shifts in retention time). Peptides unique to or highly upregulated in the infected samples were sequenced by tandem MS analysis at optimized collision activated dissociation (CAD) energy. If product ion spectra contained insufficient sequence information, peptide samples were re-analyzed after on-column derivatization with N-hydroxysuccinimidyl-3-pyridylacetate (SPA), which helps to elucidate sequence information by promoting b-type ions and distinguishing between the isobaric amino acid residues K and Q [28]. Protein database searching was performed (<http://www.mann.embl-heidelberg.de>) to determine the source protein of the sequenced peptides. The sequence of the allocated peptides was confirmed using synthetic peptides.

For quantitation of the amount of a peptide in a sample, new peptide mixtures were generated, derived from approximately 10^9 cells that were spiked with known amounts of two synthetic peptide standards (Angiotensin III and Oxytocin; Sigma-Aldrich, St Louis, MO, USA) directly after peptide isolation to correct for sample loss during the subsequent processing of the samples. Quantitation of peptides in the mixture was performed on the summed intensity of the different charge states of a peptide ($[M+H]^+ + [M+2H]^{2+} + [M+3H]^{3+}$) at the expected retention time including possible oxidized forms, relative to the response obtained for the internal standards in full scan single ms µLC-ESI-MS analysis. Quantitation was based assuming equal specific responses (counts per pmol) and equal losses during sample processing for all peptides and the internal synthetic standards.

HLA-A*0201 Binding

The T2 peptide-binding assay was performed as described previously [25]. Briefly, T2 cells were incubated overnight with peptide at various concentrations of pep-

tide or in PBS alone. Peptide binding to the otherwise unstable HLA-A*0201 molecule will increase its expression at the cell surface, which was detected by the FITC-conjugated HLA*0201 specific monoclonal antibody (mAb) BB7.2 on a FACScan and analyzed using CellQuest software (Becton Dickinson, San Jose, CA, USA). Peptide binding was calculated as the fluorescence index (FI): $FI = [(mean\ fluorescence\ in\ the\ presence\ of\ peptide) - (mean\ fluorescence\ without\ peptide)] / (mean\ fluorescence\ without\ peptide)$. In this assay, at a peptide concentration of 100 µM the FI is indicative of a low ($0.5 < FI < 1.0$), intermediate ($1.0 < FI < 1.7$) or high ($FI > 1.7$) affinity binding of the HLA-A*0201 molecule to the peptide [25].

Protein Expression and Localization

BSM cells were infected with MV for 24 hours, fixed with 2% paraformaldehyde, washed and incubated with 0.1-M glycine for 10 minutes, and permeabilized with 0.1% saponin/1% BSA in PBS. Immunostaining was performed with polyclonal rabbit-anti-IFI (RIVM, The Netherlands) and goat-anti-Hsp90β (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) as primary antibodies, and donkey-anti-rabbit-IgG-FITC and donkey-anti-goat-IgG-FITC as secondary antibodies (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). Stained cells were analyzed on a FACSCalibur flow cytometer using CellQuest software (Becton Dickinson).

The subcellular localisation of IFI-6-16 and Hsp90β was studied by confocal microscopy as described previously [29] using the antibodies described above, and propidium iodide (PI) (100 µg/ml) for DNA counterstaining. FITC and PI fluorescence were pseudocolored in green and red respectively and high intense fluorescence (Channels 150–255) was pseudocolored as yellow in an overlay.

Tetrameric Complexes and FACS-Staining

MHC-peptide tetramers were generated essentially as described by Tan *et al.* [30]. In brief, HLA-A*0201 heavy chain containing a specific biotinylation site and β₂-microglobulin were expressed in large amounts in *E. coli* transformed with the appropriate plasmids, isolated by French press treatment, dissolved in 8 M of urea, and diluted into refolding buffer (400-mM L-arginine, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, 2 mM EDTA, 100 mM Tris, pH 8) containing high concentrations of synthetic peptide. The generated monomeric, soluble HLA-A*0201-peptide complexes were biotinylated by the BirA enzyme (Avidity, Denver, CO, USA) followed by purification by gel filtration. Tetramer formation was performed by addition of PE-conjugated streptavidin (Sigma, St Louis, MO, USA), or APC conjugated streptavidin (Molecules Probes, Eugene, OR, USA) at a molar ratio of 4:1.

Tetramer staining of CBMC, PBMC or isolated CD8⁺ T-cell fractions (positively selected with immunomagnetic beads [Miltenyi Biotech, Auburn, CA, USA] according to manufacturers instruction) was performed by incubating cells for 15 minutes at 37°C with the appropriate tetramer in FACS buffer (1% FCS in PBS) followed with an additional incubation with PerCP- or APC-conjugated anti-CD8 plus anti-CD3-FITC for 15 minutes at 37°C. Stained samples were subsequently washed with cold FACS buffer and approximately 30,000 events were measured in the lymphocyte gate combined with either a CD8⁺ gate or a CD8⁺/CD3⁺ gate on a FACSCalibur flow cytometer (Becton Dickinson) and analyzed using CellQuest software (Becton Dickinson). Control samples for the tetramer staining were the CD8⁺ enriched cellular fractions of PBMCs from HLA-mismatched donors.

IFN γ Enzyme-Linked Immunospot Assay

Peripheral blood mononuclear cells were pulsed with 10 μ M of self-peptide or with control peptide for 1 hr before adding the cells to duplicate wells of polyvinylidene difluoride backed plates (MAIP S 45; Millipore, Bedford, MA, USA) coated with anti-IFN- γ antibody (Mabtech, Cincinnati, OH, USA). For PBMC of MV patients 1×10^4 – 1×10^5 cells were seeded per well, and for healthy control MV-immune donors 1×10^5 – 2.5×10^5 cells were seeded per well. Cells were incubated for 20–24 hours at 37°C, 5% CO₂. Plates were washed, developed with chromogenic alkaline phosphatase substrate after the two-step incubation with biotinylated anti-IFN- γ and streptavidin antibodies, respectively (Mabtech), and screened for IFN γ producing spot forming cells (SFC). Peripheral blood mononuclear cells obtained from Gambian patients in the acute phase were directly tested. For detection of epitope-specific memory responses in individuals after recovery, isolated PBMC from the same donors after recovery need to be stimulated first (A.J., unpublished observations). In the stimulated cultures, cells were grown for 10 days in complete RPMI 1640/10% FCS, after pulsing with 10 μ M peptide, in the presence of 10% IL-2 (Lymphocult T; Biotest AG, Dreieich, Germany) and 5 ng/ml IL-7 (Genzyme, Cambridge, MA, USA). IL-2 was added at day 3 and day 7. At day 10 cells were pulsed with 10 μ M peptide before adding them to Elispot plates and overnight incubation.

RESULTS

MV Infection Induces or Upregulates Abundant Expression of Two Self-Peptides Binding to HLA-A*0201

To study possible shifts in the display of peptides bound by HLA-A*0201 molecules as a result of MV infection,

HLA-A*0201-associated peptides were eluted from HLA-A*0201 molecules isolated from the homozygous B-LCL BSM prior to and 48-hours after MV infection. The comparison of the thousands of peptides present in both peptide mixtures revealed several individual peptide species that were only present in the post-infection peptide sample. Through collision activated dissociation (CAD) and tandem MS analysis of these MV-induced peptide species, amino acid sequences were obtained from a limited number of peptides, including three viral peptides [25]. Another MV-induced peptide, detected as its [M+H]⁺ ion at *m/z* 1007.5 and sequenced as SL_xM-SWSAL_xL_x (Figure 1A–E; L_x stands for either L or I), did not match a MV protein sequence but showed full homology with amino acids 74–82 of the human type I IFN inducible protein 6-16 (IFI-6-16₇₄₋₈₂, *i.e.*, SLMSWSAIL). The identification of the biologic peptide ion at *m/z* 1007.5 as IFI-6-16₇₄₋₈₂ was confirmed after comparison with synthetic SLMSWSAIL, which had the same μ LC retention time and CAD spectra (data not shown).

During the subtractional analysis of HLA-A*0201 eluted peptides prior to and after MV infection we also observed several peptide species of which the expression was enhanced or reduced by MV infection of the cell. Notably, MV infection did not alter the expression of MHC class I molecules itself on infected BSM cells (data not shown). One naturally processed non-viral peptide that was at least five times enhanced in the infected peptide mixture, was detected at its [M+H]⁺ ion at *m/z* 1071.8 and was sequenced as L_xL_xD[K/Q] [K/Q]VE[K/Q]V (Figure 1F–J). This sequence was homologous to amino acids 570–578 from the β chain of human Hsp90 (Hsp90 β ₅₇₀₋₅₇₈, *i.e.*, ILDKKVEKV), and their identity was confirmed using synthetic ILDKKVEKV.

In subsequent repetitive peptide isolation experiments, the presence and abundance of IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ in HLA-A*0201 on MV-infected and uninfected cells was further studied. Consistently, no IFI-6-16₇₄₋₈₂ was detected in peptide mixtures obtained from uninfected cells, while the amount of IFI-6-16₇₄₋₈₂ recovered per aliquot of 10⁹ infected cells varied between 0.9 pmol and 5 pmol, corresponding to an average density of 500 and 3000 copies per cell respectively. Here-with this epitope ranks as a relatively abundant HLA class I ligand [31, 32]. The amount of Hsp90 β ₅₇₀₋₅₇₈ recovered from uninfected cells varied between 7 pmol and 24 pmol per 10⁹ cells, corresponding to 4000 and 14,000 copies per cell, respectively. These data indicate that the basal level of expression of Hsp90 β ₅₇₀₋₅₇₈ is already high and variable. However, the amount of this peptide recovered from infected cells varied between 7 pmol and 70 pmol per 10⁹ cells, corresponding to 4000 and 40,000 copies per infected cell, respectively, quali-




FIGURE 1 Detection and identification of two naturally processed self-peptides in HLA-A*0201 that are induced or upregulated by measles virus (MV) infection. Peptides were isolated from BSM cells prior to and after MV infection and fractionated into four large fractions by rpHPLC as described in material and methods. Shown are total (A, C, F, and H) and extracted (B, D, G, and I) ion currents recorded in rpHPLC-fraction 2 (F–I) and 4 (A–D) from MV-infected (C, D, H, and I) and uninfected (A, B, F, and G) cells, and CAD analyses of SPA-derivatized ions (E, J). A peptide species at m/z 1007.5

was present in HPLC-fraction 4 from the MV infected cells (D) and absent in the corresponding HPLC-fraction of the uninfected cells (B). CAD analysis of this peptide after on-column SPA-derivatization was determined to be $SL_xMSWSAL_xL_x$ (where L_x stands for either L or I)(E). A peptide species at m/z 1071.8 was at least five times more abundant in HPLC-fraction 2 of the infected cells (I) than in the corresponding HPLC-fraction of the uninfected cells (G). The sequence of this peptide was determined by CAD analysis to be $IL_xD[K/Q][K/Q]VE[K/Q]V$ (J).

ifying the expression of this self-peptide on MV-infected cells as very highly abundant [31, 32]. Even though in none of these experiments the initial fivefold enhancement in the expression of Hsp90 β ₅₇₀₋₅₇₈ following MV infection was reached, the general trend of a MV-induced increase in its expression was confirmed.

To determine the affinity of the HLA-A*0201 molecule for IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ we used an assay based on the capacity of a peptide to stabilize the cell surface expression of empty unstable HLA-A*0201 molecules on the TAP-deficient T2 cells. We found that even though the affinity of HLA-A*0201 for both self-peptides was lower than for other CTL epitopes tested (Table 1), IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ are still bound by this restriction element with a relatively high affinity (FI > 1.7).

Expression and Subcellular Localization of IFI-6-16 and Hsp90 β Before and After MV Infection

The observed upregulation of two self-peptides in HLA-A*0201 on MV-infected cells suggests that the expression of their parental proteins becomes modulated by MV infection. To study this we first assessed the intracellular expression of the IFI-6-16 and the Hsp90 β proteins in infected and uninfected BSM cells by flow cytometry. IFI-6-16-specific immunofluorescence was readily detected in uninfected BSM cells, and was enhanced as a result of viral infection (Figure 2A), indicating that in contrast to its peptide, expression of IFI-6-16 protein is not restricted to MV-infected cells. Intracellular staining for HSP90 β was found in untreated BSM

TABLE 1 Peptide binding affinity to HLA-A*0201

Peptide	Sequence	Affinity to HLA-A*0201 (FI at 100 μ M)
IFI-6-16 ₇₄₋₈₂	SLMSWSAIL	2.3
Hsp90 β ₅₇₀₋₅₇₈	ILDKKVEKV	3.1
HPV 16 E7 ₈₆₋₉₃	TLGIVCPI	5.7
Flu-M ₅₇₋₆₅	GILGFVFTL	4.6
MV-C ₈₄₋₉₂ (L ₈₅ P)	KPWESPQEI	0.1

Abbreviations: FI = fluorescence index; Flu-M₅₇₋₆₅ = Influenza matrix protein₅₇₋₆₅; Hsp90 β = heat shock protein 90 β chain; HLA = human leukocyte antigen; HPV 16 E7₈₆₋₉₃ = human papillomavirus 16 E7 protein₈₆₋₉₃; IFI-6-16 = type I interferon inducible protein; MV = measles virus.

cells, and was upregulated after MV infection (Figure 2B).

We next investigated whether MV infection induced a shift in the subcellular distribution of IFI-6-16 and Hsp90 β by studying their compartmentalization with confocal microscopy in MelJuso cells, which can be readily infected with MV [29]. In uninfected cells IFI-6-16 localizes to the nucleus and the cytoplasm, where it is present in tubular structures while absent from the perinuclear region, a pattern showing a marked resemblance with the structure of the endoplasmic reticulum (Figure 3A). MV infection induced small changes in the subcellular distribution of IFI-6-16 towards a more granular like pattern in both nuclei and cytoplasm (arrowhead in Figure 3B), together with a minor increase of the fluorescence intensity in the nucleus (Figures 3A and 3B, see also insets). In uninfected cells Hsp90 β was predominantly detected as a fine granular, sometimes diffuse fluorescence pattern in the cytoplasm (Figure 3C). A clear enhanced cytoplasmic fluorescence together with a decreased localization in the nucleus was observed in MV-infected cells (Figures 3C and 3D, see also insets, and legends for different gain settings for Figures 3C and 3D). Taken together, the induced presentation of an IFI-6-16-derived epitope in HLA-A*0201 molecules on MV-infected cells was only accompanied by subtle changes in IFI-6-16 protein expression after infection. In contrast, the upregulation of Hsp90 β ₅₇₀₋₅₇₈ in HLA-A*0201 as a result of MV infection paralleled an overall increased expression of the parental protein Hsp90 β , and a further accumulation in the cytosol.

T Cells Recognizing IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ are Present but Functionally Silent in the Naïve and Adult Human T-Cell Repertoire

To determine whether CD8⁺ T cells capable of recognizing IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ in the context of HLA-A*0201 molecules are present in the human T-cell repertoire, we constructed tetrameric complexes of HLA-A*0201 molecules containing these self-peptides. First, we studied the presence of CD8⁺ T cells that were




FIGURE 2 Modulation of intracellular expression of IFI-6-16 and Hsp90 β proteins by measles virus (MV) infection. Immunofluorescent staining for IFI-6-16 (A) and Hsp90 β (B) was assessed in the presence of specific antibodies and FITC labeled conjugate (yellow, green), or of FITC labeled conjugate only (pink, blue), in MV infected (yellow, pink) or uninfected (green, blue) BSM cells.

able to bind to the HLA-A*0201/IFI-6-16₇₄₋₈₂ and the HLA-A*0201/Hsp90 β ₅₇₀₋₅₇₈ tetrameric complexes in naïve CBMC enriched for CD8⁺ cells. In all HLA-A*0201 positive cord blood donors ($n = 3$), HLA-A*0201/IFI-6-16₇₄₋₈₂ positive CD8⁺ T cells could be detected with frequencies ranging from 0.2%–0.4% of the total CD8⁺ T-cell population, whereas for HLA-A*0201/Hsp90 β ₅₇₀₋₅₇₈ frequencies ranged from less than 0.1% to 1.1% of all CD8⁺ T cells (Figures 4A–4C). These findings suggest that measurable numbers of IFI-6-16₇₄₋₈₂ and in some cases also Hsp90 β ₅₇₀₋₅₇₈ specific




FIGURE 3 Minor and major shifts in the subcellular localization of IFI-6-16 and Hsp90 β , respectively, following measles virus (MV) infection. Uninfected (A and C) and MV-infected (B and D) MelJuso cells were immunostained for intracellular IFI-6-16 (A and B) or Hsp90 β (C and D). Immunofluorescence for IFI-6-16 and Hsp90 β is illustrated as green and DNA fluorescence as red. IFI-6-16 is present in the cytoplasm as rubular structures (arrows) and absent in the perinuclear region, a more granular-like staining becomes evident after MV infection (arrowhead). A high fluorescence intensity for IFI-6-16 is present in the nucleus of non-infected

and MV-infected cells (inlets A and B where nuclear immunolocalization was selected [box] and pseudocolored). A granular, sometimes diffuse immunofluorescence is seen for Hsp90 β in non-infected and MV-infected cells (C, D). MV infection enhances the Hsp90 β -fluorescence intensity (note: gain-settings of the confocal microscope were adjusted in D, reducing total Hsp90 β specific fluorescence, compare uninfected mononuclear cell in control sample (C, middle) with uninfected mononuclear cells in infected sample (D, top-left), and reduces the presence of Hsp90 β in the nucleus (inlets C and D). Bar represents 10 μ m.




FIGURE 4 IFI-6-16₇₄₋₈₂ and HSP90β₅₇₀₋₅₇₈ binding CD8⁺ T cells are present in peripheral blood mononuclear cells (PBMC) from HLA-A*0201-positive healthy individuals. Illustrated are CD8⁺ enriched cord blood mononuclear cells (CBMC) from three HLA-A*0201 positive cord blood donors (A–C) and CD8⁺ enriched PBMC from three MV immune HLA-A*0201 positive adults (D–F) stained with CD8 and/or CD3 without tetramer, with HLA-A*0201/IFI-6-16₇₄₋₈₂ tetramer or HLA-A*0201/Hsp90β₅₇₀₋₅₇₈ tetramer as indicated. Illustrated are dot plots of CD8⁺ cells (D–F) or CD8⁺/CD3⁺ cells (A–C) in the lymphgate with tetramer staining on the x-axis and CD8 staining on the y-axis. The percentages of tetramer positive CD8⁺ cells are indicated in the upper right quadrant of the dot plot. Staining patterns observed in HLA-A*0201 positive individuals were always brighter than those obtained in HLA-A*0201 negative controls (not shown) and therefore considered as genuinely epitope-specific.

CTL precursors are present in the human T-cell repertoire in HLA-A*0201 positive individuals at birth.

Next, we assessed the levels of HLA-A*0201/IFI-6-16₇₄₋₈₂-binding and HLA-A*0201/Hsp90β₅₇₀₋₅₇₈-binding CD8⁺ T cells in peripheral blood from HLA-A*0201 positive adults with a history of MV infection or vaccination in childhood ($n = 8$). With the exception of one highly reactive donor (not shown), in all donors (illustrated for three in Figures 4D–4F) frequencies of tetramer staining CD8⁺ T cells were consistently low (<0.1% CD8⁺ T cells). Stimulation of PBMC from these adult donors with the IFI-6-16₇₄₋₈₂ or Hsp90β₅₇₀₋₅₇₈ peptide for approximately 24 hours did not result in the detection of peptide-specific IFN-γ producing SFC in

TABLE 2 IFN- γ producing cells upon peptide stimulation in MV patients

MV patient	Peptide	Acute phase	Recovery
M300	IFI-6-16 ₇₄₋₈₂	3 (0)*	28 (23)
	Hsp90 β ₅₇₀₋₅₇₈	16 (0)*	25 (23)
	MV-H ₃₀₋₃₈	16 (0)*	45 (23) [†]
M571	IFI-6-16 ₇₄₋₈₂	13 (3) [†]	32 (17) [†]
	Hsp90 β ₅₇₀₋₅₇₈	13 (3) [†]	13 (17)
	MV-H ₃₀₋₃₈	14 (3) [†]	27 (17) [†]

* SFC found in the presence of peptide, between bracket background SFC (found in the absence of peptide).

[†] $p < 0.05$

[‡] $p < 0.01$

Number of cells seeded per well were 3×10^4 (M300, acute phase), 1×10^5 (M300, recovery), 5×10^4 (M571, acute phase) and 1×10^4 (M571, recovery).

Abbreviations: Hsp90 β = heat shock protein 90 β chain; IFI-6-16 = type I interferon inducible protein; IFN = interferon; MV = measles virus; SFC = spot forming cell.

ELISPOT (detection limit <2 SFC/ 10^5 PBMC, data not shown). These data suggest that even though basal levels are generally lower than those found in naïve cord blood, potentially autoreactive T cells recognizing IFI-6-16₇₄₋₈₂ or Hsp90 β ₅₇₀₋₅₇₈ in the context of HLA-A*0201 are present but functionally unresponsive in the adult human MV-immune CD8⁺ T-cell repertoire.

IFN- γ Producing Effector Cells Recognizing IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ are Present in MV Patients

To assess whether the altered expression of self-peptides in MHC class I could lead to the functional activation of autoreactive T cells recognizing the self-ligand *in vivo*, PBMC from two HLA-A*0201 positive MV patients were tested for their capacity to produce IFN- γ upon stimulation with the IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ peptides in ELISPOT. We found that IFN- γ producing SFC specific for both peptides can be present in PBMC from acutely infected patients up to a level of 20 and 53 SFC per 10^5 PBMC for IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈, respectively (Table 2). In the recovery samples of these two MV patients (5–7 weeks after the rash), the IFI-6-16₇₄₋₈₂-specific IFN- γ response was maintained, but no peptide-specific memory response against the Hsp90 β ₅₇₀₋₅₇₈ peptide could be detected in this assay. As a control, peptide-specific responses against several other peptides were maintained in both patients during this period (shown for MV-H₃₀₋₃₈; Table 2). To study if MV infection also induced the expansion of the small numbers of CD8⁺ T cells binding to the HLA-A*0201/IFI-6-16₇₄₋₈₂ and the HLA-A*0201/Hsp90 β ₅₇₀₋₅₇₈ tetrameric complexes, PBMCs obtained from five other HLA-A*0201 positive MV patients during acute infection and upon recovery were stained with these tetramers. In all patients the pattern and

frequencies of CD8⁺ tetramer binding cells were similar to those of uninfected healthy adults (data not shown). Thus, whereas natural MV infection does not induce an apparent expansion of the IFI-6-16₇₄₋₈₂ or Hsp90 β ₅₇₀₋₅₇₈ specific CD8⁺ T cells in the peripheral blood, it does induce the functional activation of these cells.

DISCUSSION

In this study we provide direct evidence for a mechanism underlying the virally induced activation of autoreactive T cells. We found that MV infection causes a shift in the MHC class I peptide display on human B-lymphocytes, a natural target cell of this virus [33]. In addition to the appearance of MHC class I presentation of viral peptides [25], MV infection also altered the presentation of peptides derived from self-proteins. Here, we describe the identification of two self-peptides in HLA-A*0201, IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈, the expression of which was either induced or upregulated to abundant levels following MV infection. Their parental proteins, IFI-6-16 and the β chain of Hsp90, respectively, were so far not implicated in MV pathogenesis.

IFI-6-16, a putative 12 kD transmembrane protein was first identified from mRNA that was highly induced in cells treated with type I IFN [34, 35], and poorly, if at all, in response to IFN- γ [35, 36]. The here reported subcellular localization of IFI-6-16 in untreated cells suggests a function in the endoplasmic reticulum and the nucleus. Notably, the IFI-6-16₇₄₋₈₂ epitope was undetectable in uninfected cells, and became only apparent after MV infection. The minor increase of IFI-6-16 protein expression after MV infection, known to induce the production of type I IFNs [37–39], as well as the observed shift towards cytosolic localization of this protein, could point at an altered intracellular processing route of IFI-6-16 leading to the de novo generation of IFI-6-16₇₄₋₈₂/HLA-A*0201 complexes in MV-infected cells.

The Hsp90 $\alpha\beta$ heterodimer is an abundant cytosolic chaperone protein essential for the viability of eukaryotic cells, and upregulated under stress conditions such as heat shock and inflammation [26]. As could be expected for a subunit of a protein interacting with the proteasome [40, 41], we readily found cytoplasmic staining for Hsp90 β in uninfected cells. Also we found basal, yet variable amounts of the HLA-A*0201 presented Hsp90 β ₅₇₀₋₅₇₈ epitope in uninfected cells, indicating that the Hsp90 β protein normally intersects the MHC class I processing pathway. Since the Hsp90 $\alpha\beta$ protein is a component of the stress response, variation of the basal Hsp90 β ₅₇₀₋₅₇₈ epitope level could well be attributed to subtle differences in stress conditions between individual semi-large scale nonautomated cell cultures ($>10^9$ cells) needed for peptide isolation. Apparently, the additional

stress of a viral infection further enhances the formation of Hsp90 β ₅₇₀₋₅₇₈/HLA-A*0201 complexes on MV-infected cells. The Hsp90 β ₅₇₀₋₅₇₈ enhancement is paralleled by an increased expression and further cytosolic accumulation of the parental protein, indicating a rise in the amount of Hsp90 β available for proteasomal degradation and further MHC class I processing after MV infection. Using the DNA microarray technology, others have recently included several genes of the IFN and stress response systems to be upregulated by MV infection [37]. Our study directly highlights the consequences hereof for MHC-peptide presentation.

Owing to their altered infection-related generation and their relatively high-affine binding to HLA-A*0201, the IFI-6-16₇₄₋₈₂ or Hsp90 β ₅₇₀₋₅₇₈ epitopes become potential target epitopes for autoreactive CD8⁺ T cells. T cells binding to either IFI-6-16₇₄₋₈₂ or Hsp90 β ₅₇₀₋₅₇₈ presented in the context of HLA-A*0201 were indeed detectable in the human T-cell repertoire, apparently having escaped from negative selection during thymic residence. Since we found that both parental proteins are expressed under normal conditions in cells of lymphoid and melanocyte origin and participate in the host's stress response, we assume that IFI-6-16 and Hsp90 β do not have a tissue specific expression pattern but are also present in the thymus. Lack of tolerance induction may therefore point at crypticity of their respective epitopes in the thymus, being expressed either too poorly or not at all, to induce clonal deletion [42]. Processing events unique to the thymus may underlie such crypticity [43].

We found that while considerable in cord blood, basal levels of IFI-6-16₇₄₋₈₂-HLA-A*0201 tetramer or Hsp90 β ₅₇₀₋₅₇₈-HLA-A*0201 tetramer binding CD8⁺ T cells had declined to almost undetectable levels in healthy MV-immune adults. Downregulation of T-cell receptors (TCR) expressed by potentially autoreactive T cells is one of the mechanisms proposed for the induction of peripheral tolerance [44, 45], and thus could explain this decline during life. Notably, the low numbers of tetramer-binding CD8⁺ T cells present in MV immune adults were functionally inert in ELISPOT, but could be expanded in the presence of specific peptide and cytokines (C. Herberts, unpublished results), indicating that IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ specific cells are silently present in the periphery, yet have the capacity to proliferate.

Autoreactive T cells in the periphery will only become harmful when activated. In two HLA-A*0201 positive MV patients we found preliminary evidence for such activation of IFI-6-16₇₄₋₈₂ and Hsp90 β ₅₇₀₋₅₇₈ specific CD8⁺ T cells. Self-peptide specific IFN- γ responses were detected in these patients in ELISPOT (Table 2), but were not correlated with an increase in the number of self-tetramer-staining CD8⁺ T cells *ex vivo*. Although

these observations should be extended to more patients and controls, they do indicate that natural MV infection may lead to the functional activation of IFI-6-16₇₄₋₈₂- and Hsp90 β ₅₇₀₋₅₇₈-specific effector cells, but without measurable expansion. Thus, altered MHC self-peptide presentation, probably combined with molecular danger signals [20], can break tolerance of autoreactive T cells during viral infection.

The role of activated autoreactive CD8⁺ T cells during viral infections is currently unknown. They could help clear the virus by eliminating infected cells. Once differentiated into memory T cells, they could also assist in the accelerated clearance of subsequent infections with the same or other infectious agents, provided these induce the same epitopes to be enhanced [46, 47]. In this context, autoreactive T cells specific for the self protein Hsp65 have been proposed to play an immunoregulatory role at sites of inflammation and autoimmune tissue destruction [48].

On the other hand, virally activated autoreactive T cells may also be immunopathogenic by initiating autoimmunity [49]. In this respect, activated autoreactive T cells responding against virus-enhanced MHC class I self-ligands (e.g., Hsp90 β ₅₇₀₋₅₇₈) could potentially be more harmful than those against virus-induced self-peptides of which presentation is restricted to infected cells only (e.g., IFI-6-16₇₄₋₈₂), since the former may also attack non-infected tissue and may continue to do so even after recovery from infection. Notably, we found that IFN- γ responses against IFI-6-16₇₄₋₈₂, but not Hsp90 β ₅₇₀₋₅₇₈, could still be detected upon recovery from MV infection. Whether this indicates that self-reactivity against ubiquitous self-epitopes is more tightly controlled than that against peptides only emerging during infection is presently unknown.

Measles virus infection has been associated with several autoimmune diseases including multiple sclerosis [7]. Preliminary findings suggest the presence of moderately elevated numbers of CD8⁺ T cells binding to the HLA-A*0201/IFI-6-16₇₄₋₈₂ or HLA-A*0201/Hsp90 β ₅₇₀₋₅₇₈ tetramers in individuals suffering from multiple sclerosis (C. Herberts, unpublished observations). Further functional characterization of these potentially autoreactive T cells is needed to gain insight into their possible role, either pathologic or protective, in (the onset of) autoimmunity.

Notably, infection with Epstein-Barr virus, which is also associated with multiple sclerosis, was found to induce MHC presentation of a peptide derived from the small heat shock protein α B-crystallin, a candidate autoantigen in multiple sclerosis [24]. Furthermore, di Marzo Veronese *et al.* [5] have described the induction of HLA-A2 restricted self-peptides derived from the cytoskeleton protein vinculin following chronic infection of

B-LCL cells with human immunodeficiency virus-1 (HIV-1). Similar to our findings, effector cells recognizing (one of) these peptides were readily detectable in a number of HLA-A2-positive HIV-1 infected individuals. Collectively, these data indicate that both acute and chronic viral infections can lead to the upregulation or induction of self-peptides in MHC molecules, and can be associated with the (temporary) activation of autoreactive effector cells recognizing these peptides. More insight into the expression and immunogenicity of self-epitopes associated with viral infections and their functionality, be it regulatory or pathogenic, may lead towards the development of better immunotherapeutic intervention strategies.

ACKNOWLEDGMENTS

We thank Dr. P. Hoogerhout for the synthesis of peptides and P. Hansasuta for his help with the tetramer synthesis.

REFERENCES

1. Aichele P, Brduscha-Riem K, Oehen S, Odermatt B, Zinkernagel RM, Hengartner H, Pircher H: Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. *Immunity* 6:519, 1997.
2. Sandberg JK, Franksson L, Sundback J, Michaelsson J, Petersson M, Achour A, Wallin RP, Sherman NE, Bergman T, Jornvall H, Hunt DF, Kiessling R, Karre K: T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. *J Immunol* 165:25, 2000.
3. Kamradt T, Mitchison NA: Tolerance and autoimmunity. *N Engl J Med* 344:655, 2001.
4. Ehl S, Hombach J, Aichele P, Rulicke T, Odermatt B, Hengartner H, Zinkernagel R, Pircher H: Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. *J Exp Med* 187:763, 1998.
5. di Marzo Veronese F, Arnott D, Barnaba V, Loftus DJ, Sakaguchi K, Thompson CB, Salemi S, Mastroianni C, Sette A, Shabanowitz J, Hunt DF, Appella E: Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. *J Exp Med* 183:2509, 1996.
6. Sinha AA, Lopez MT, McDevitt HO: Autoimmune diseases: the failure of self tolerance. *Science* 248:1380, 1990.
7. ter Meulen V, Liebert UG: Measles virus-induced autoimmune reactions against brain antigen. *Intervirology* 35:86, 1993.
8. Liebert UG, ter Meulen V: Synergistic interaction between measles virus infection and myelin basic protein peptide-specific T cells in the induction of experimental allergic encephalomyelitis in Lewis rats. *J Neuroimmunol* 46:217, 1993.
9. Link H, Sun JB, Wang Z, Xu Z, Love A, Fredrikson S, Olsson T: Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. *J Neuroimmunol* 38:63, 1992.
10. Johnson RT, Griffin DE, Hirsch RL, Wolinsky JS, Roedenbeck S, Lindo SI, Vaisberg A: Measles encephalomyelitis—clinical and immunologic studies. *N Engl J Med* 310:137, 1984.
11. Rott O, Herzog S, Cash E: Autoimmunity caused by host cell protein-containing viruses. *Med Microbiol Immunol (Berl)* 183:195, 1994.
12. Ohteki T, Hessel A, Bachmann MF, Zakarian A, Sebzda E, Tsao MS, McKall-Faienza K, Odermatt B, Ohashi PS: Identification of a cross-reactive self ligand in virus-mediated autoimmunity. *Eur J Immunol* 29:2886, 1999.
13. Hiemstra HS, Schloot NC, van Veelen PA, Willemen SJ, Franken KL, van Rood JJ, de Vries RR, Chaudhuri A, Behan PO, Drijfhout JW, Roep BO: Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. *Proc Natl Acad Sci USA* 98:3988, 2001.
14. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J, Melief CJ, Cerny A: Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. *J Exp Med* 190:169, 1999.
15. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. *Science* 255:1261, 1992.
16. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carrizosa A, Kim BS: Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. *Nat Med* 3:1133, 1997.
17. Salemi S, Caporossi AP, Boffa L, Longobardi MG, Barnaba V: HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. *J Exp Med* 181:2253, 1995.
18. Roncarolo MG, Levings MK: The role of different subsets of T regulatory cells in controlling autoimmunity. *Curr Opin Immunol* 12:676, 2000.
19. Rose NR: Infection, mimics, and autoimmune disease. *J Clin Invest* 107:943, 2001.
20. Marzinger P: Tolerance, danger, and the extended family. *Annu Rev Immunol* 12:991, 1994.
21. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, Craft J, Hooft VH, Plotz P: Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. *Proc Natl Acad Sci USA* 97:9209, 2000.
22. Santori FR, Arsov I, Vukmanovic S: Modulation of CD8(+) T cell response to antigen by the levels of self MHC class I. *J Immunol* 166:5416, 2001.
23. Ovsyannikova IG, Johnson KL, Naylor S, Poland GA: Isolation and rapid identification of an abundant self-peptide

- from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection. *J Immunol Methods* 246:1, 2000.
24. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geurtskens SB, van Noort JM: EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. *J Immunol* 162:129, 1999.
 25. van Els CA, Herberts CA, van der HE, Poelen MC, van Gaans-van den Brink JA, van der Kooi A, Hoogerhout P, ten Hove GJ, Meiring HD, de Jong AP: A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. *Eur J Immunol* 30:1172, 2000.
 26. Buchner J: Supervising the fold: functional principles of molecular chaperones. *FASEB J* 10:10, 1996.
 27. van der Heeft E, ten Hove GJ, Herberts CA, Meiring HD, van Els CA, de Jong AP: A microcapillary column switching HPLC-Electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. *Anal Chem* 70:3742, 1998.
 28. Cardenas MS, van der HE, de Jong AP: On-line derivatization of peptides for improved sequence analysis by micro-column liquid chromatography coupled with electrospray ionization-tandem mass spectrometry. *Rapid Commun Mass Spectrom* 11:1271, 1997.
 29. Herberts CA, Stittelaar KJ, van der Heeft E, van Gaans-van den Brink JA, Poelen MC, Roholl PJ, van Alphen LJ, Melief CJ, de Jong AP, van Els CA: A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. *J Gen Virol* 82:2131, 2001.
 30. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MF: A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. *J Immunol* 162:1827, 1999.
 31. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amato J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. *Eur J Immunol* 23:1215, 1993.
 32. Crotzer VL, Christian RE, Brooks JM, Shabanowitz J, Sertliffe RE, Marto JA, White FM, Rickinson AB, Hunt DF, Engelhard VH: Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. *J Immunol* 164:6120, 2000.
 33. Griffin DE, Bellini WJ: Measles Virus. In Fields BN, Knipe DM, Howley PM (eds): *Fields Virology*. Philadelphia: Lippincott-Raven, 1996.
 34. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR: Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. *Cell* 38:745, 1984.
 35. Kelly JM, Porter AC, Chernajovsky Y, Gilbert CS, Stark GR, Kerr IM: Characterization of a human gene inducible by alpha- and beta-interferons and its expression in mouse cells. *EMBO J* 5:1601, 1986.
 36. Kelly JM, Gilbert CS, Stark GR, Kerr IM: Differential regulation of interferon-induced mRNAs and c-myc mRNA by alpha- and gamma-interferons. *Eur J Biochem* 153:367, 1985.
 37. Bolt G, Berg K, Blixenkrone-Moller M: Measles virus-induced modulation of host-cell gene expression. *J Gen Virol* 83:1157, 2002.
 38. Dhib-Jalbut SS, Cowan EP: Direct evidence that interferon-beta mediates enhanced HLA-class I expression in measles virus-infected cells. *J Immunol* 151:6248, 1993.
 39. Jacobson S, McFarland HF: Measles virus persistence in human lymphocytes: a role for virus-induced interferon. *J Gen Virol* 63:351, 1982.
 40. Wagner BJ, Margolis JW: Age-dependent association of isolated bovine lens multicatalytic proteinase complex (proteasome) with heat-shock protein 90, an endogenous inhibitor. *Arch Biochem Biophys* 323:455, 1995.
 41. Tsubuki S, Saito Y, Kawashima S: Purification and characterization of an endogenous inhibitor specific to the Z-Leu-Leu-Leu-MCA degrading activity in proteasome and its identification as heat-shock protein 90. *FEBS Lett* 344:229, 1994.
 42. Sercarz EE: Processing creates the self. *Nat Immunol* 3:110, 2002.
 43. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza G, Wraith DC, Watts C: Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. *Nat Immunol* 3:169, 2002.
 44. Ferber I, Schonrich G, Schenkel J, Mellor AL, Hammerling GJ, Arnold B: Levels of peripheral T cell tolerance induced by different doses of tolerogen. *Science* 263:674, 1994.
 45. Schonrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, Malissen B, Hammerling GJ, Arnold B: Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. *Cell* 65:293, 1991.
 46. Lanzavecchia A, Sallusto F: Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. *Science* 290:92, 2000.
 47. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B: Response of naive and memory CD8+ T cells to antigen stimulation in vivo. *Nat Immunol* 1:47, 2000.
 48. van Eden W, van der Zee R, Paul AG, Prakken BJ, Wendling U, Anderton SM, Wauben MH: Do heat shock proteins control the balance of T-cell regulation in inflammatory diseases? *Immunol Today* 19:303, 1998.
 49. Marrack P, Kappler J, Kotzin BL: Autoimmune disease: why and where it occurs. *Nat Med* 7:899, 2001.